Abstract. Osteosarcoma (OS) is identified as the most commonly diagnosed malignant cancer of bone, and has approximately three million new cases annually. miR-26a plays an important role in the development of various types of cancer. We investigated whether miR-26a can regulate the migration and invasion of OS by targeting high-mobility group A1 HMGA1. Western blot analysis was used to identify the changes of protein levels. Reverse transcription-quantitative PCR was used to test expression levels of genes and miR-26a. Luciferase reporter assay was used to test the specific target gene of miR-26a. Transwell assay was employed to determine the migration and invasion of OS cell lines. In the present study, miRNA-26a was frequently downregulated in OS tissues and cells. Overexpression of miR-26a inhibited cell migration and invasion in vitro. In addition, miR-26a downregulated HMGA1 by targeting its 3'-UTR and knockdown of HMGA1 significantly suppressed the migration and invasion of two osteosarcoma cell lines in vitro. miR-26a suppressed the migration and invasion of OS cells by targeting HMGA1, suggesting that miR-26a/HMGA1 axis provides a new prospective therapeutic strategy for OS.
Introduction
Osteosarcoma (OS) is a common malignant bone cancer type, with approximately 3,000,000 new cases annually (1) . This type of cancer often occurs in adolescents and children, and individuals over the age of 50 years are also susceptible to the disease (2) . OS can be treated through surgery, chemotherapy and radiation and it is reported that the newly developed immuno therapies, such as chimeric antigen receptor-engineered T cells or immune checkpoint obstruction, can be employed to treat OS (3) . Combination chemotherapies play an important role in the treatment of OS (4) . Although almost all of the patients can accept the resection surgery, the OS recurrences remain high and often metastasize (5) , and less than 20% of patients survive four years after recurrence (6, 7) . Therefore, it is imperative to develop a novel therapeutic strategy to treat osteosarcoma more effectively.
MicroRNAs (miRNAs) are 21-22 nucleotide long non-coding RNAs and more than 1,000 miRNAs are expressed and function in human cells (8) . miRNAs have been proven to play important roles in many biological processes, such as apoptosis, proliferation and differentiation (9) . miRNAs regulate translation or splicing of their target mRNAs by binding to their 3'-UTRs (10) . miR-26a is one of these miRNAs. Ma et al reported that the downregulation of miR-26a increased hepatocellular carcinoma growth and pulmonary metastasis (11) . It was reported that miR-26a was significantly downregulated in bladder cancer (BC) tissues, and that the upregulation of miR-26a could suppress BC cell migration and invasion by modulating procollagenlysine, 2-oxoglutarate 5-dioxygenase (12) . However, no relative evidence of miR-26a in osteosarcoma cells has been documented thus far.
The high-mobility group A (HMGA) family is comprised of three proteins: HMGA1a, HMGA1b and HMGA2 (13) . HMGA proteins do not possess transcriptional ability, but they can change the chromatin structure to regulate the expression of various genes (14, 15) . HMGA family proteins play pivotal roles in various biological processes, such as proliferation, differentiation, and chromatin structure (16) . The expression levels of HMGA proteins are very low in normal tissues and cells. By contrast, a higher expression of HMGA is the hallmark of cancer (17, 18) . Puca et al reported that HMGA1 was miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1 upregulated in colon tumor stem cell lines compared with the normal tissues (19) . They identified that HMGA1 silencing could contribute to stem cell quiescence by increasing p53 levels (19) . The overexpression of HMGA1 could increase cell proliferation and the stemness-related genes of the A2780 ovarian cancer stem line (20) . Recent research has shown that HMGA1 acted as a target gene of miR-142 in regulating OS cell growth (21) . However, whether HMGA1 was a target of miR-26a in regulating OS cell migration and invasion remains to be determined.
In the present study, we aimed to detect the role of miR-26a and HMGA1 in OS. We also explored the mechanism of miR-26a in regulating OS progression. The results showed that miRNA-26a was frequently downregulated in OS tissues and cells and the re-expression of miR-26a could suppress cell migration and invasion in vitro. Moreover, we identified that the expression of HMGA1 was decreased by miR-26a through targeting its 3'-UTR and knockdown of HMGA1 inhibited the migration and invasion of OS cells. Taken together, our study provides a new potential therapeutic target for OS treatment.
Materials and methods
Tissues and cell lines. Fifty-two pairs of human OS samples were obtained from patients who underwent surgery at the People's Hospital of Weifang (Weifang, China) from January, 2010 to December, 2016. All the patients provided written informed consent to participate in the study. Tissues obtained were immediately frozen in liquid nitrogen, stored at -80˚C. This study was approved by the Ethics Committee of People's Hospital of Weifang.
Osteosarcoma cell line U2OS differentiated cell groups have high migratory capacity, and the normal human osteoblastic cell line hFOB 1.19 rarely divide, or divide at the limit of 39.5˚C low migratory capacity. The cells were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Biowest, South America Origin), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA; Merck KGaA, Munich, Germany, respectively) in a humidified incubator with 5% CO 2 at 37˚C.
Oligonucleotide transfection. The miR-26a mimic, inhibitor or negative control was transfected into cells for 48 h using Lipofectamine ® 2000 according to the manufacturer's protocols. The primer sequences used were: miR-26a mimic forward, UUCAAGUAAUCCAGGAUAGGCU, and reverse, CCUAUCCUGGAUUACUUGAAUU. miR-26a inhibitor forward, ATGTTCTTTAATGTCGGGAGC, and reverse, AA AGAATTCTGCCCGTGAC. To overexpress HMGA1, vectors containing HMGA1 were transfected into cells for 48 h using RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocols.
Western blot analysis. The cells were harvested and lysed with RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Proteins were separated by 10% SDS-PAGE gel and transformed onto PVDF membranes (Invitrogen; Thermo Fisher Scientific, Inc.). The membranes were incubated with the primary antibody HMGA1, (dilution, 1:1,000; cat. no. ab168260), β-actin, (dilution, 1:1,000; cat. no. ab8227) (Abcam, Cambridge, UK) overnight at 4˚C after being blocked with 5-10% skimmed milk at temperature for 2 h. The membrane was then incubated with secondary antibody (dilution, 1:2,000; cat. no. sc-516102-CM; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) conjugated to horseradish peroxidase goat anti-mouse at room temperature for 2 h. Signals were visualized using the enhanced chemiluminescence kit (EMD Millipore, Billerica, MA, USA). The intensities of individual bands were analyzed by densitometry using ImageJ software (National Institutes of Health, Bethesda, MD, USA) and normalized to the β-actin level.
Reverse transcriptase-quantitative PCR. Total RNA was extracted from cells or tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instruction. Complementary DNA was synthesized using PrimeScript RT reagent kit (Takara, Dalian, China) and RT-qPCR was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd., Dalian, China) with the Stratagene Mx3000P real-time PCR system (Agilent Technologies, Inc., Santa Clara, CA, USA). The primer sequences used were: miR-26a forward, TTGGATCCGTCAGAAATTCTCTCCC GAGG, and reverse, GGTCTAGATGTGAACTCTGGTGTT GGTGC. HMGA1 forward, GGCCCAAATCGACCATAAA GG, and reverse, GGACAAATCATGGCTACCCCT. U6 forward, GCTTCGGCAGCACATATACTAAAAT, and reverse, CGCTTCACGAATTTGCGTGTCAT. β-actin forward, CGTGACATTAAGGAGAAGCTG, and reverse, CT GAAGCATTTGCGGTGGAC. The thermocycler conditions were: 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and an annealing/elongation step at 60˚C for 30 sec. U6 and β-actin were used as internal controls to standardize miRNA and mRNA, respectively. The 2 -ΔΔCq method was used to detect the relative expression of miR-26a and HMGA1.
Luciferase reporter assay. HMGA1-3'UTR was amplified and cloned into pmir-GLO vector (Promega Corporation, Madison, WI, USA). Mutation of HMGA1-3'UTR was generated using QuikChange Site-Directed Mutagenesis kit (Stratagene; Agilent Technologies, Inc.). For luciferase reporter assay, pmir-GLO-HMGA1-3'UTR-WT or mutant plasmid plus miR-26a mimic or miR-control were transfected into U2OS cells. After 48 h of transfection, cells were collected and relative luciferase activity was measured by the dual-luciferase reporter assay system (Promega Corporation). The firefly luciferase activity was normalized to Renilla luciferase activities.
Migration and invasion assay in vitro.
Cell migration and invasion assays were performed in a 24-well Transwell plate (pore size, 8 µm; Corning Incorporated, Corning, NY, USA). Cells (1x10 5 ) were resuspended in 200 µl of serum-free medium and plated onto the upper chamber. The lower chamber was filled with 15% fetal bovine serum as a chemoattractant. For the invasion assay, the upper chamber was pre-coated with Matrigel (dilution, 1:3; BD Biosciences, San Jose, CA, USA). After incubation for 24 h, the cells on the upper chamber were removed, and the migratory and invasive cells on the lower chamber were fixed using formalin and stained with 0.1% crystal violet 30 min at room temperature. Finally, the cells were photographed using a Leica DC 300F positive microscope (Leica Microsystems Imaging Solutions Ltd., Cambridge, UK) at x20 magnification.
Statistical analysis.
The results are presented as the mean ± standard deviation (SD). Statistical analysis was conducted using the SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Each experiment was repeated at least three times. Student's t-test or post hoc test after one-way analysis of variance (ANOVA) in SPSS were used to analyze the differences between the groups. Correlation between mRNA and miRNA were estimated using the Spearman's correlation method. P<0.05 was considered to indicate a statistically significant difference.
Results

miRNA-26a is frequently downregulated and HMGA1 is upregulated in OS.
To determine the role of miR-26a in OS, we tested the expression level of miR-26a in OS and normal tissues in a group of 52 OS patients by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The results showed that a relative miR-26a expression was frequently decreased in OS tissues compared with their adjacent non-tumor (NT) tissues (Fig. 1A) . Then, we detected the expression of miR-26a in OS cells. The results showed that miR-26a was also significantly decreased compared with normal bone cells (hFOB 1.19) in both OS cell lines (Fig. 1B) . We did not detect the expression of miR-26a in the various tumor stages.
HMGA1 expression in OS and normal tissues in a group of 52 OS patients by RT-qPCR.
The results stated that the relative HMGA1 expression was frequently increased in OS tissues compared with their adjacent NT tissues (Fig. 1C) . The relationship between miR-26a and HMGA1 expression was negatively correlated (Fig. 1D) .
Overexpression of miR-26a suppresses cell migration and invasion in vitro.
To investigate the potential role of miR-26a in the migration and invasion of OS, we selected U2OS cells for further investigation. Firstly, miR-26a mimic was transfected into U2OS cells to overexpress miR-26a. The successful overexpression of miR-26a was determined by RT-qPCR ( Fig. 2A) . Subsequently, we used a Transwell assay to detect the cell migration and invasion after U2OS cells were transfected with miR-26a mimic. Fig. 2B shows the overexpression of miR-26a significantly suppressed cell migration and invasion. These findings indicated that miR-26a suppressed cell migration and invasion in vitro.
HMGA1 is identified as the target of miR-26a.
To elucidate the potential mechanism of miR-26a in suppressing OS migration and invasion, we searched for the potential target genes of miR-26a using the bioinformatics algorithm TargetScan (http://www.targetscan.org/vert_71/). HMGA1, containing a potential binding site at 1317-1324 bp, was selected for experimental validation (Fig. 3A) . Luciferase reporter assay showed that the luciferase activity was significantly reduced when U2OS cells were co-transfected with pmir-GLO-HMGA1-3'UTR (WT) and miR-26a (P<0.01). There was no effect on cells co-transfected with pmir-GLO-HMGA1-3'UTR (MUT) and miR-26a (Fig. 3B) . We further examined the protein expression of HMGA1 in U2OS cells after transfected with miR-26a mimic or miR-26a inhibitor by using western blot analysis. The results showed that overexpression of miR-26a reduced HMGA1 expression and knockdown of miR-26a increased HMGA1 expression (Fig. 3C ). These findings indicated that HMGA1 was a direct target of miR-26a in OS cells.
Effect of HMGA1 on OS cell migration and invasion regulated by miR-26a in vitro.
Firstly, the HMGA1 siRNA or negative control was transfected into the U2OS cells to investigate the effect of HMGA1 on the OS cells. The expression of HMGA1 was detected by western blot analysis (Fig. 4A ) and RT-qPCR (Fig. 4B) . We then used a Transwell assay to test the relative cell migration and invasion in U2OS cells. The results showed that the migration and invasion of U2OS cells transfected with the HMGA1 siRNA was significantly decreased compared with the cells transfected with the negative control (Fig. 4C and D) . Then, we investigated the effect of HMGA1 on OS cell migration and invasion downregulated by miR-26a. We found that HMGA1 could reverse the inhibitory effect of miR-26a on OS cell migration and invasion ( Fig. 4E and F) .
Discussion
OS is the most common pattern of bone tumor (22) . Although efforts have been made to explore the underlying mechanism of OS tumorigenesis, the survival rate of OS remains low (23) . Therefore, it is imperative to identify new biomarkers for the development of effective therapeutic methods for OS.
In the present study, we explored the function of miR-26a and HMGA1 on human OS. Firstly, we examined the expression level of miR-26a in OS tissues and cells. The results showed that the expression level of miR-26a was significantly decreased in OS tissues and cells compared with the normal ones. Then we overexpressed miR-26a by transfecting the miR-26a mimic into the U2OS cells. We found that overexpression of the miR-26a could suppress the invasion and migration of U2OS cells. Using the TargetScan online prediction and luciferase reporter assay, we further identified and confirmed that HMGA1 was the target of miR-26a, and miR-26a could suppress the expression of HMGA1.
The miR-26 family is comprised of miR-26a and miR-26b. They play important roles in biological processes, such as cell cycle and differentiation (24, 25) . The miR-26a has been identified downregulated in various human cancers. Lu et al (26) identified that the miR-26a inhibits OS tumor growth in vivo and in vitro by regulating Jagged1, which is consistent with our study. The expression of miR-26a was decreased in esophageal squamous cell carcinoma (ESCC) tumor tissues compared with the adjacent normal tissues and the miR-26a could suppress the proliferation and metastasis of ESCC (27) . In addition, miR-26a also plays a role in the metabolism of lipids and glucose, modulating insulin sensitivity in type 2 diabetes (28) . The miR-26a also plays a crucial role in pancreatic cancer (29) , cholangiocarcinoma (30), breast cancer (31) and non-small lung cancer (32). Yu et al (33) (C) The U2OS cells was transfected with miR-26a mimic and inhibitor. The protein levels of HMGA1 in U2OS cells were determined using western blot analysis. HMGA1, targeting high-mobility group A1; U2OS, two osteosarcoma cell line; WT, wild-type; MUT, mutant-type.
reported that miR-26a was significantly upregulated in pituitary cancer tissues. There may exist other potential downstream targets of miR-26a in human OS.
HMGA1 can regulate various genes due to its ability to alter the chromatin structure. It is reported that the CCNE2 was a downstream target of HMGA1. The HMGA1 and CCNE2 regulate the cell migration through the Hippo core kinases in breast cancer (34) . The HMGA1 activated cell stemness and crucial migration-related genes. The HMGA1 gene expression was related with the poor prognosis in breast cancer (35) . HMGA1 overexpression is a hallmark of human cancer and exhibits a pivotal role in cell transformation (36) . Our research is also consistent with that report. In the present study, we identified that the knockdown of HMGA1 significantly suppressed the migration and invasion of U2OS cells. In medulloblastoma (MB), cdc25A is a target of HMGA1 and HMGA1 interacts with cdc25A promoter. The knockdown of HMGA1 suppresses the MB cell invasion, migration and growth (37) . The mutation of HMGA1 gene can influence its functions.
There are some drawbacks to the study. The number of patient samples is relatively small. Our research lacks clinical experiments. Thus, further study is required to address these aspects.
In conclusion, we identified that miRNA-26a was frequently downregulated in OS tissues and cells. The overexpression of miR-26a suppresses cell migration and invasion in vitro. Moreover, the HMGA1 is a target of miR-26a and the knockdown of HMGA1 inhibits the migration and invasion of U2OS cells. The miR-26a/HMGA1 axis provides new insight into the pathogenesis of OS and a biomarker for the treatment of OS.
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